Inhibition of antipyrine metabolism by interferon.
Antipyrine clearance was measured before and 1 day after administration of a single intramuscular dose of recombinant human leukocyte alpha A interferon. In the nine patients studied, antipyrine clearance was reduced after interferon from 0.49 (0.21-1.13) ml kg-1 min-1 (median (range)) to 0.41 (0.20-1.07) ml kg-1 min-1, P less than 0.01. In individual patients, the decrement in antipyrine clearance was variable, ranging from 5-47% (median, 16%). This study provides the first direct evidence that interferon inhibits hepatic oxidative drug metabolism in humans and alerts clinicians to the possibility of potentially toxic drug-drug interactions.
D000328:Adult; D000983:Antipyrine / Q000037:antagonists & inhibitors / Q000378:metabolism*; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy; D006521:Hepatitis, Chronic / Q000188:drug therapy; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology* / Q000627:therapeutic use; D008099:Liver / Q000378:metabolism; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use
D007370:Interferon Type I; D011994:Recombinant Proteins; D000983:Antipyrine